Sanofi Under Preliminary Probe in France Over Possible Market Manipulation, Source Says
07 Novembro 2023 - 10:56AM
Dow Jones News
By Helena Smolak
France's financial prosecutors have opened a preliminary
investigation into Sanofi over possible dissemination of false or
misleading information and share-price manipulation, a judicial
source said Tuesday.
The preliminary investigation by the French Financial
Prosecutor's Office was opened in March, the source said. Details
were first reported by French media outlet La Lettre, which said
the allegations relate to Sanofi's launch in 2017 of the
anti-inflammatory drug Dupixent, developed in cooperation with the
American biotechnology company Regeneron Pharmaceuticals.
In response, Sanofi said it wasn't aware nor has it been
contacted by the French Financial Prosecutor's Office regarding any
preliminary investigation into its 2017 accounts or other
matters.
Regeneron didn't immediately respond to a request for
comment.
Sanofi generated sales of 2.85 billion euros ($3.06 billion)
from Dupixent in the third quarter, a 33% increase compared with
the same period last year. The company expects revenue from
Dupixent--its best-selling drug--to be close to EUR13 billion in
2024.
At 1310 GMT, Sanofi shares were down 1.5% to EUR83.63.
Write to Helena Smolak at helena.smolak@wsj.com
(END) Dow Jones Newswires
November 07, 2023 08:41 ET (13:41 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Sanofi (NASDAQ:SNY)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024